A
EWTX icon

AlphaQuest’s Edgewise Therapeutics EWTX Stock Holding History

AlphaQuest’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,143
Closed -$177K – 689
2025
Q4 		$177K Sell
7,143
-7,131
-50% -$143K 0.01% 1513
2025
Q3 		$232K Sell
14,274
-7,116
-33% -$101K 0.02% 1322
2025
Q2 		$280K Buy
21,390
+12,032
+129% +$174K 0.03% 920
2025
Q1 		$206K Buy
9,358
+7,155
+325% +$188K 0.02% 980
2024
Q4 		$58.8K Sell
2,203
-6,832
-76% -$218K 0.01% 1255
2024
Q3 		$241K Buy
9,035
+7,293
+419% +$145K 0.02% 986
2024
Q2 		$31.4K Buy
1,742
+1,064
+157% +$18.6K ﹤0.01% 1230
2024
Q1 		$12.4K Buy
+678
New +$10.8K ﹤0.01% 1066

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlphaQuest's EWTX Position: Q1 2026 in Review

AlphaQuest sold out of Edgewise Therapeutics (EWTX) in Q1 2026, closing a stake of 7,143 shares — an estimated $177K sold.

AlphaQuest first reported a position in EWTX in Q1 2024 and held it in 8 quarters. The position peaked at $280K in Q2 2025. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • AlphaQuest reported no remaining Edgewise Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 7,143 Edgewise Therapeutics shares in Q1 2026, an estimated $177K.
  • AlphaQuest first reported a position in Edgewise Therapeutics in Q1 2024 and held it in 8 quarters.
  • AlphaQuest's Edgewise Therapeutics position peaked at $280K in Q2 2025.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.